Research institution
University Health Network, Toronto Clinical Trials
Studies where University Health Network, Toronto is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 254Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication
Platform of Randomized Adaptive Clinical Trials in Critical Illness
PRACTICAL is a randomized multifactorial adaptive platform trial for acute hypoxemic respiratory failure (AHRF). This platform trial will evaluate novel interventions for patients with AHRF across a range of severity states…
- Conditions
- Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
- Trial name
- PRACTICAL (NCT05440851)
- Testing
- Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL)
- Where
- 103 sites in United States, Australia and 8 more
- Volunteers
- 6,250 people
- Sponsor
- University Health Network, Toronto
Autoimmune Hepatitis
Belimumab in Autoimmune Hepatitis
Background: Autoimmune hepatitis (AIH) is a rare chronic and lifelong liver disease. Untreated, disease progresses to end-stage cirrhosis and the focus of therapy is with immunosuppression.
- Trial name
- BELief (NCT06381453)
- Testing
- Belimumab Auto-Injector [Benlysta]
- Where
- 6 sites in Canada
- Volunteers
- 48 people
- Sponsor
- University Health Network, Toronto
Extubation
EXtubation Related Complications - the EXTUBE Study (EXTUBE)
EXTUBE is an international, multicentre, prospective cohort study evaluating the incidence, risk factors, and outcomes of extubation-related complications and describing clinical practices related to extubation after general…
- Trial name
- EXTUBE (NCT06442930)
- Where
- 35 sites in United States, Australia and 7 more
- Volunteers
- 3,000 people
- Sponsor
- University Health Network, Toronto
Long COVID, Post COVID-19 Condition
Effect of Hi-OxSR for the Treatment of Post COVID Condition
The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction.
- Conditions
- Long COVID, Post COVID-19 Condition, Post Acute Sequelae of COVID-19
- Trial name
- RECLAIM-HiOxSR (NCT06928506)
- Testing
- Hi-OxSR device, Hi-Ox device
- Where
- 3 sites in Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Hypogonadism, Prostate Cancer
Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients
Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in…
- Trial name
- REVIVE (NCT07535905)
- Testing
- Tamoxifen
- Where
- Canada
- Volunteers
- 96 people
- Sponsor
- University Health Network, Toronto
Triple-Negative Breast Cancer (TNBC)
Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC
This study is a phase I/II open-label randomized clinical trial to examine whether administration of isunakinra (EBI-005), a modified recombinant IL1 receptor antagonist, can sensitize human TNBC to the PD1…
- Trial name
- NCT07698106
- Testing
- Group 1-Isunakinra
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Head and Neck Squamous Cell Carcinoma (HNSCC)
Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck Cancers
The ORION study will evaluate a novel treatment approach for patients with recurrent, metastatic, oligometastatic, or locoregionally incurable head and neck squamous cell carcinoma (HNSCC).
- Trial name
- ORION (NCT07888816)
- Testing
- Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer Recurrent, Prostate Cancer
Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.
- Trial name
- SHAPE-PSMA (NCT06508567)
- Testing
- High Dose Rate Brachytherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Prostate Adenocarcinoma, Iliac Nodal Disease
Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response
This prospective, single-arm feasibility study will include patients with prostate cancer that have controlled local disease diagnosed with oligorecurrent para-aortic nodal disease and/or common iliac nodal disease detected by…
- Conditions
- Prostate Adenocarcinoma, Iliac Nodal Disease, Para-aortic Lymph Node Metastasis, Para-aortic Nodal Disease
- Trial name
- EASY (NCT06831032)
- Testing
- Adaptive radiotherapy using SBRT
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- University Health Network, Toronto
Palliative Cancer
Prophylaxis for Emetogenic radioTherapy With Akynzeo
This phase II, prospective study evaluates whether prophylactic treatment with Akynzeo can reduce nausea and vomiting in patients receiving palliative radiotherapy in which the gastrointestinal GI tract is within the radiation…
- Trial name
- PRÊT (NCT07882966)
- Testing
- Akynzeo
- Where
- Canada
- Volunteers
- 188 people
- Sponsor
- University Health Network, Toronto
Completed, with results posted
All –Kidney Transplant Recipients, Post-transplant Diabetes Mellitus
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
This study will be a randomized, double-blind, placebo-controlled clinical trial comparing the SGLT2 inhibitor dapagliflozin to placebo in 52 kidney transplant recipients (KTR) with or without pre-existing type 2 diabetes (T2D)…
- Conditions
- Kidney Transplant Recipients, Post-transplant Diabetes Mellitus, Type 2 Diabetes
- Trial name
- INFINITI2019 (NCT04965935)
- Testing
- Dapagliflozin 10 MG Oral Tablet
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- University Health Network, Toronto
Lungcancer
A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
MEK162 has shown significant inhibition of tumor growth as a single agent in NSCLC xenograft models in mice and human cancer cells in vitro, which have KRAS and/or other mutations.
- Trial name
- MEK162 (NCT02185690)
- Testing
- Binimetinib, Pemetrexed, Carboplatin
- Where
- 4 sites in Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Type 2 Diabetes Mellitus, Heart Failure
ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure
This study aims to elucidate the mechanisms whereby the SGLT2i "ertugliflozin" modifies cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients with type 2 diabetes and heart failure (T2D-HF).
- Trial name
- ERADICATE-HF (NCT03416270)
- Testing
- Ertugliflozin
- Where
- 3 sites in Canada, Netherlands
- Volunteers
- 34 people
- Sponsor
- University Health Network, Toronto
Obstructive Sleep Apnea
Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications
Sugammadex or neostigmine are given at the end of the surgery to reverse neuro muscular blocking drugs (NMBD). This study will evaluate whether reversal of NMBD with sugammadex is associated with faster recovery than neostigmine…
- Trial name
- Sugammadex (NCT03679611)
- Testing
- Sugammadex Sodium, Neostigmine
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Osteoporosis, HIV
Bone Health in Aging HIV Infected Women
Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1.
- Conditions
- Osteoporosis, HIV, Menopause
- Trial name
- BEING (NCT02815566)
- Testing
- tenofovir-alafenamide-emtricitabine, tenofovir-emtricitabine
- Where
- 7 sites in Canada, Italy
- Volunteers
- 34 people
- Sponsor
- University Health Network, Toronto